Literature DB >> 31668201

Viral Hemorrhagic Fevers Other than Ebola and Lassa.

Marco Iannetta1, Antonino Di Caro1, Emanuele Nicastri1, Francesco Vairo1, Honorati Masanja2, Gary Kobinger3, Ali Mirazimi4, Francine Ntoumi5, Alimuddin Zumla6, Giuseppe Ippolito7.   

Abstract

Viral hemorrhagic fevers represent a group of diseases caused by enveloped RNA viruses. The epidemiology is broadly variable, ranging from geographically localized to more diffuse infections. Viral hemorrhagic fevers are classified as category A bioweapon agents by the Centers for Disease Control and Prevention. Viral hemorrhagic fevers are severe febrile illnesses with hemorrhagic phenomena. Laboratory diagnosis takes place in highly specialized reference laboratories. Treatment is essentially supportive. In this article, we focus the attention on yellow fever and viral hemorrhagic fevers other than Ebola and Lassa virus diseases that have been described elsewhere in this issue.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arenavirus; Bunyavirus; Filovirus; Flavivirus; Hantavirus; Marburg; Viral hemorrhagic fever

Mesh:

Year:  2019        PMID: 31668201     DOI: 10.1016/j.idc.2019.08.003

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  10 in total

Review 1.  Travel/Tropical Medicine and Pandemic Considerations for the Global Surgeon.

Authors:  Christian Sandrock; Shahid R Aziz
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2020-05-08       Impact factor: 2.802

2.  Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent.

Authors:  Alexa M Kaufer; Torsten Theis; Katherine A Lau; Joanna L Gray; William D Rawlinson
Journal:  Pathology       Date:  2020-09-30       Impact factor: 5.306

Review 3.  Probiotic Effects against Virus Infections: New Weapons for an Old War.

Authors:  Aroa Lopez-Santamarina; Alexandre Lamas; Alicia Del Carmen Mondragón; Alejandra Cardelle-Cobas; Patricia Regal; José Antonio Rodriguez-Avila; José Manuel Miranda; Carlos Manuel Franco; Alberto Cepeda
Journal:  Foods       Date:  2021-01-09

4.  Novel therapeutic approaches toward Hantaan virus and its clinical features' similarity with COVID-19.

Authors:  Harvinder Singh; Harpinder Kaur; Bikash Medhi
Journal:  Indian J Pharmacol       Date:  2020 Sep-Oct       Impact factor: 1.200

5.  Identification of Novel Antiviral Compounds Targeting Entry of Hantaviruses.

Authors:  Jennifer Mayor; Giulia Torriani; Olivier Engler; Sylvia Rothenberger
Journal:  Viruses       Date:  2021-04-16       Impact factor: 5.048

6.  Viral haemorrhagic fevers and malaria co-infections among febrile patients seeking health care in Tanzania.

Authors:  Sima Rugarabamu; Susan F Rumisha; Gaspary O Mwanyika; Calvin Sindato; Hee-Young Lim; Gerald Misinzo; Leonard E G Mboera
Journal:  Infect Dis Poverty       Date:  2022-04-25       Impact factor: 10.485

7.  Monkeypox outbreak: after COVID-19, another challenge for the hemostatic system?

Authors:  Marco Marietta; Valeria Coluccio; Mario Luppi
Journal:  Intern Emerg Med       Date:  2022-10-04       Impact factor: 5.472

8.  Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus.

Authors:  Jennifer Mayor; Olivier Engler; Sylvia Rothenberger
Journal:  Microorganisms       Date:  2021-06-15

9.  Emerging and Reemerging Infectious Diseases: Global Overview.

Authors:  Alimuddin Zumla; David S C Hui
Journal:  Infect Dis Clin North Am       Date:  2019-12       Impact factor: 5.982

10.  Arenavirus as a potential etiological agent of odontogenic tumours in humans.

Authors:  Marco de Feo; Cristina De Leo; Umberto Romeo; Paola Muti; Giovanni Blandino; Silvia Di Agostino
Journal:  J Exp Clin Cancer Res       Date:  2020-02-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.